Safety and Pharmacokinetics of CXCR4 Peptide Antagonist, LY2510924, in Combination with Durvalumab in Advanced Refractory Solid Tumors

Purpose: This was an open-label phase 1a study assessing the maximum tolerated dose (MTD), safety, and tolerability of CXCR4 peptide antagonist, LY2510924, administered in combination with durvalumab in patients with advanced refractory solid tumors. Methods: Patients received LY2510924 at 20, 30, o...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Pancreat Cancer
Main Authors: O'Hara, Mark H., Messersmith, Wells, Kindler, Hedy, Zhang, Wei, Pitou, Celine, Szpurka, Anna M., Wang, Dan, Peng, Sheng-Bin, Vangerow, Burkhard, Khan, Anis A., Koneru, Mythili, Wang-Gillam, Andrea
Formato: Artigo
Idioma:Inglês
Publicado em: Mary Ann Liebert, Inc., publishers 2020
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7097682/
https://ncbi.nlm.nih.gov/pubmed/32219196
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/pancan.2019.0018
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados